Regulatory challenges with biosimilars: an update from 20 countries

Ann N Y Acad Sci. 2021 May;1491(1):42-59. doi: 10.1111/nyas.14522. Epub 2020 Nov 21.

Abstract

The World Health Organization (WHO) issued guidelines for the regulatory evaluation of biosimilars in 2009 and has provided considerable effort toward helping member states implement the evaluation principles in the guidelines into their regulatory practices. Despite this effort, a recent WHO survey (conducted in 2019-2020) has revealed four main remaining challenges: unavailable/insufficient reference products in the country; lack of resources; problems with the quality of some biosimilars (and even more with noninnovator products); and difficulties with the practice of interchangeability and naming of biosimilars. The following have been identified as opportunities/solutions for regulatory authorities to deal with the existing challenges: (1) exchange of information on products with other regulatory authorities and accepting foreign licensed and sourced reference products, hence avoiding conducting unnecessary (duplicate) bridging studies; (2) use of a "reliance" concept and/or joint review for the assessment and approval of biosimilars; (3) review and reassessment of the products already approved before the establishment of a regulatory framework for biosimilar approval; and (4) setting appropriate regulatory oversight for good pharmacovigilance, which is essential for the identification of problems with products and establishing the safety and efficacy of interchangeability of biosimilars.

Keywords: WHO; biosimilar; challenges; regulation; survey.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biosimilar Pharmaceuticals / standards*
  • Drug Approval*
  • Guidelines as Topic
  • Health Information Exchange
  • Humans
  • Pharmacovigilance*
  • Surveys and Questionnaires
  • World Health Organization

Substances

  • Biosimilar Pharmaceuticals